Navigation Links
Immediate Treatment of Early MS Patients with Betaferon,Significantly Delayed Permanent Disability

-breaking results,” said Darlene Jody, M.D., President of Bayer HealthCare’s Specialized Therapeutics Global Business Unit. “In the past year, Betaferon® has received approval around the world for use in patients with the earliest signs of MS. We intend to submit this novel data for inclusion in our label. Regulatory approval would further differentiate Betaferon® from other products in the market place and strengthen our position.”

About BENEFIT
BENEFIT is a multi-center trial conducted at 98 sites in 20 countries and included patients presenting with a single clinical episode suggestive of MS. A total of 468 patients with a first clinical demyelinating event suggestive of MS and typical MRI findings were randomized to receive either 250 micrograms of interferon beta-1b (Betaferon®) every other day or placebo as a subcutaneous injection in a double blind fashion. The placebo-controlled treatment period lasted up to 24 months or up to the time when patients were diagnosed with clinically definite MS. All study participants were then invited to participate in a follow-up study with Betaferon® to prospectively assess the impact of such immediate versus delayed treatment with Betaferon® on the long-term course of the disease for a total observation time of five years.

Results from a prospectively planned analysis of patients three years after the first event suggestive of MS showed that immediate treatment with Betaferon® after the first event suggestive of MS reduced the risk for confirmed EDSS progression by 40 percent over three years compared to delayed treatment. At three years, patients who initiated Betaferon® treatment immediately were 41 percent less likely to progress to clinically definite MS versus patients who began treatment later. These results confirm the findings of the placebo-controlled BENEFIT study.

At the end of three years, 73 percent of patients were
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
2. OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation
3. First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron Significantly Delayed Permanent Disability
4. Point of Care Strep Tests Speed Treatment, Lower Costs
5. Rapid HIV Testing Increases Possibility of Treatment
6. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
7. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
Post Your Comments:
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/11/2014)... July 11, 2014 ... Safety & Health Expo 2014 were a ... to London , plus ... exhibition.          (Logo: ... )      (Photo: ...
(Date:7/10/2014)... July 11, 2014  Major advances in radiation ... are being highlighted in a three-day Oncology Summit ... from 10-12 July, 2014.  Renowned national and international cancer experts ... practices and exchange knowledge on modern technologies making ... efficient. The Summit will address ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... Aug. 17, 2011 Reportlinker.com announces that ... in its catalogue: Levosimendan ... http://www.reportlinker.com/p0483048/Levosimendan---Comprehensive-patent-search.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Eliminate unnecessary ... patent information. Pipeline Developer is ...
... 16, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... KRYSTEXXA® (pegloticase) Phase III clinical studies in patients with ... The Journal of the American Medical Association ( ... resulted in significant and sustained reductions in uric acid ...
Cached Medicine Technology:Levosimendan - Comprehensive Patent Search 2Levosimendan - Comprehensive Patent Search 3Levosimendan - Comprehensive Patent Search 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:7/11/2014)... City, UT (PRWEB) July 11, 2014 WWTrek ... work at the Kilimanjaro Kids Community in Tanzania. Opened in ... goats, 150 chickens, and two cows. HOP Founder, Dean Cardinale, ... education for some of the orphaned children he encountered while ... HOP Team visited the children, who have all made astounding ...
(Date:7/11/2014)... Francisco shows that an "expressive therapy" group intervention ... with HIV disclose their health status and improves ... quality of their relationships., "Medication alone is totally ... Machtinger, MD, director of the Women,s HIV Program ... are on effective antiretroviral therapy but far too ...
(Date:7/11/2014)... July 11, 2014 Recently, iFitDress.com, a ... occasion outfits, has released its new collection of ... the company has announced that all these beautiful items ... The deadline of the special offer is July 22. ... major officials pay close attention to customer satisfaction. On ...
(Date:7/11/2014)... July 11, 2014 Organic Crop ... being launched into the limelight over the past decade. ... was once considered to be an alternative food eaten ... are now purchasing organic food.” Organic crop farmers have ... vegetables, grains, nuts and herbs over the past five ...
(Date:7/11/2014)... personalized medicine may be just around the corner, thanks ... Yu and scientists at Massachusetts General Hospital and Harvard ... Science , Yu and her colleagues report how ... streams of six patients. Some of these deadly cancer ... and establish secondary tumors in vital organs such as ...
Breaking Medicine News(10 mins):Health News:Human Outreach Project Sees Incredible Progress in the Kilimanjaro Kids Community 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 4
... Beneficial bacteria found in healthy women help to reduce the ... more difficult for the virus to spread, boosting the possibility ... against HIV. , The findings come from physicians and scientists ... Medical Center, who worked together in an effort to learn ...
... a national healthcare,management and technology company, has renewed ... West Virginia to provide Revenue Cycle,Management (RCM), ASP ... physician groups., St. Mary,s Medical Center provides ... in several specialties. MED3OOO,s subsidiary,MED3OOO Health Solutions of ...
... CYT, MONTREAL, Feb. 7 /PRNewswire-FirstCall/ - CryoCath (TSX: CYT), will,hold a ... (Eastern Time) on Thursday, February 14, 2008. The Company,will report its results ... 14., DATE: ... ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), ... announced today that its CareCentrix(R),ancillary care benefit management ... homecare contract with CIGNA HealthCare, which will,provide for ... CIGNA,members through January 31, 2011. The extension amends ...
... employee benefit Increasing animal obesity, more and better pet care ... ... The insurance industry is,going to the dogs ... and cats., Officials ... friends and the growth trends for pet insurance are,only going to accelerate ...
... close ties with parents is obviously good for preschoolers, ... the preschoolers are better able to control their own ... , Thats the finding of a new study conducted ... in the January/February 2008 issue of the journal Child ...
Cached Medicine News:Health News:'Good bacteria' in women give clues for slowing HIV transmission 2Health News:'Good bacteria' in women give clues for slowing HIV transmission 3Health News:St. Mary's Medical Center Renews RCM & Technology With MED3000 2Health News:CryoCath to Hold First Quarter 2008 Conference Call and Webcast 2Health News:Gentiva(R) Health Services and CIGNA HealthCare Extend National Homecare Contract Through January 31, 2011 2Health News:Gentiva(R) Health Services and CIGNA HealthCare Extend National Homecare Contract Through January 31, 2011 3Health News:PetFirst: Pet Insurance To Be More Popular in 2008 2Health News:Close ties between parents and babies yield benefits for preschoolers 2
... peripheral nerve stimulator from B. Braun Medical. ... nerve stimulator functionality for over 10 years. ... available, a unique, under-the-glove hand held remote ... Dig. It allows the anesthesia provider operating ...
... Control allows hands-free operation in nerve locator ... 5.0 mA) with SoloStim provides a wide ... control when close to nerve., ,Supported ... block products, including the clinically proven ProBloc™ ...
... your investment., ,The Centiva/5 Critical Care Ventilator ... demands of the critical care environment. The Centiva ... combining a compact size with high levels of ... space around the patients bed and allows you ...
... Mesh Elastic is a lightweight and large pore ... mesh is able to adapt to all movements ... honeycomb like structure with the large pores enables ... The mesh is ideal for incisional hernia repair ...
Medicine Products: